Meropenem

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Meropenem is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1996. DrugCentral lists 10 molecular targets, including ska, bla OXA-48 and blaNDM-1. Recorded indications include Abdominal abscess, Bacterial meningitis, Bacteroides Complicated Appendicitis and Bacteroides Peritonitis.

• Approval status: ofp (first approved 1996 by the FDA).
• Molecular targets: ska, bla OXA-48, blaNDM-1 and blaVIM-2 (10 listed in DrugCentral).
• Indications: Abdominal abscess, Bacterial meningitis, Bacteroides Complicated Appendicitis, Bacteroides Peritonitis and Complicated appendicitis and others.
• ATC code: J01DH02 (Carbapenems).
• Molecular formula: C17H25N3O5S; molecular weight 383.47 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (22)

• Abdominal abscess
• Bacterial meningitis
• Bacteroides Complicated Appendicitis
• Bacteroides Peritonitis
• Complicated appendicitis
• Complicated Skin and Skin Structure Infection
• E. Coli Complicated Appendicitis
• E. Coli Peritonitis
• H. Influenzae Meningitis
• Infection due to Pseudomonas aeruginosa
• Infectious disease of abdomen
• Klebsiella Complicated Appendicitis
• Klebsiella Pneumoniae Peritonitis
• Neisseria meningitidis meningitis
• Peptostreptococcus Complicated Appendicitis
• Peptostreptococcus Peritonitis
• Peritonitis
• Pneumococcal meningitis
• Pseudomonas Aeruginosa Complicated Appendicitis
• Streptococcal meningitis
• Streptococcal Peritonitis
• Streptococcus Complicated Appendicitis

Off-label uses (20)

• Anthrax
• Bacterial pneumonia
• Bacterial septicemia
• Cholangitis
• Clostridium Perfringens Empyema
• Complicated Urinary Tract Infections
• Diabetic Foot Infection
• Diverticulitis of gastrointestinal tract
• Gastrointestinal anthrax
• Infection by Campylobacter fetus
• Inhalational anthrax
• Melioidosis
• Neonatal meningitis
• Nocardiosis
• Nosocomial pneumonia
• Pneumonia due to Gram negative bacteria
• Pseudomonas Respiratory Tract Infection in Cystic Fibrosis
• Pyrexia of unknown origin
• Sepsis of the newborn
• Sepsis syndrome

Contraindications (5)

• Kidney disease
• Lesion of brain
• Pseudomembranous enterocolitis
• Seizure disorder
• Thrombocytopenic disorder

Mechanism & targets

Molecular targets (10)

Target	Gene	Action	Activity
Streptokinase A	ska	unknown	EC50 6.90
Beta-lactamase	bla OXA-48	unknown	Kd 6.07
Beta-lactamase NDM-1	blaNDM-1	unknown	Kd 4.96
Beta-lactamase class B VIM-2	blaVIM-2	unknown	Kd 4.92
D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6	dacC	unknown	—
Penicillin-binding protein 2	pbpA	unknown	—
D-alanyl-D-alanine carboxypeptidase DacB	dacB	inhibitor	—
Penicillin-binding protein 4	—	unknown	—
D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5	dacA	unknown	—
Penicillin-binding protein 1	ponA	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1996-06-21	FDA	—	ASTRAZENECA

ATC classification

ATC code	Therapeutic hierarchy
J01DH02	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Carbapenems
J01DH52	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Carbapenems

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Multiple organ dysfunction syndrome	2029.2
Septic shock	1678.1
Drug reaction with eosinophilia and systemic symptoms	1323.0
Drug resistance	1285.3
Pathogen resistance	1150.8
Drug ineffective	1144.9
Respiratory failure	849.5
Sepsis	794.5
Fatigue	608.8
Bronchopulmonary aspergillosis	572.6
Systemic candida	570.4
Candida infection	530.8

Chemical structure

• Molecular formula: C₁₇H₂₅N₃O₅S
• Molecular weight: 383.47 g/mol
• CAS number: —
• InChIKey: DMJNNHOOLUXYBV-PQTSNVLCSA-N
• PubChem CID: 441130

C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Meropenem used for?

DrugCentral lists the following indications for Meropenem: Abdominal abscess, Bacterial meningitis, Bacteroides Complicated Appendicitis, Bacteroides Peritonitis, Complicated appendicitis, Complicated Skin and Skin Structure Infection, E. Coli Complicated Appendicitis and E. Coli Peritonitis and others.

How does Meropenem work?

Its molecular targets in DrugCentral include ska, bla OXA-48, blaNDM-1 and blaVIM-2.

When was Meropenem first approved?

Meropenem was first approved by the FDA in 1996.

What is the chemical formula of Meropenem?

Meropenem has the molecular formula C17H25N3O5S and a molecular weight of 383.47 g/mol.

Sources

• DrugCentral drug card 1709 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL127 — compound record and bioactivity
• PubChem CID 441130 — chemical identifiers
• DrugBank DB00760 — drug record
• FDA UNII FV9J3JU8B1 — substance identity
• DailyMed: FDA labels for Meropenem — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.